WAF1/CIP1 is a universal cyclin-dependent kinase inhibitor. could be a target gene for the treatment of human hepatocellular carcinoma.
The cyclins and the cyclin-dependent kinases (cdks) are important proteins regulating the checkpoints of cell cycle progression (Hunter and Pines, 1994) . In normal cells, checkpoints in the cell cycle play an important role of guiding normal cell cycle while in cancer cells, disruption of the checkpoints is responsible to abnormal growth of cancer cells. Positive and negative regulatory mechanisms control the regulation of the checkpoints in cell cycle. A cyclin-dependent kinase inhibitor (cdki) mediates one of the negative regulations of checkpoints (Sherr and Roberts, 1995) . Recently, the p21 WAF1/CIP1 gene was cloned and mapped to the chromosome 6p21.2 region (el-Deiry et al, 1993; Noda et al, 1994) . p21 WAF1/CIP1 is considered a universal cyclin-dependent kinase inhibitor. It inhibits several cyclin-cdks complex as well as DNA synthesis by inactivating proliferation cell nuclear antigen, a subunit of DNA polymerase d (Xiong et al, 1993) . In addition, p21 WAF1/CIP1 involves in induction of cell differentiation (Skapek et al, 1995) and inhibition of tumour cell proliferation (el-Deiry et al, 1994) .
Mutation of p21 WAF1/CIP1 is rare in different types of human malignancy, therefore, it is suggested that p21 WAF1/CIP1 exerts its role in tumorigenesis mainly on expression level. It seems to be true in human hepatocellular carcinoma (HCC). Several groups studying expression of p21 WAF1/CIP1 in human hepatocellular carcinoma have documented that there were reduced p21 WAF1/CIP1 mRNA and protein levels in human HCC (Hui et al, 1997; Naka et al, 1998; Qin et al, 1998; Shi et al, 2000) . These studies suggested that disruption of p21 WAF1/CIP1 and cell cyclin-cdks complexes may contribute to malignant progression of HCC. However, the direct role of p21 WAF1/CIP1 in human HCC cells has not been explored.
In this study, we employ an expression vector of p21 WAF1/CIP1 to examine the direct effect of p21 WAF1/CIP1 on human liver cancer cells.
MATERIALS AND METHODS

Material
Minimum Eagle's medium (MEM), sodium bicarbonate, sodium pyruvate, penicillin-streptomycin, Trypsin-EDTA and Lipofectin-AMINE were purchased from GIBCO/BRL (Life Technologies, Burlington ON, Canada). Dr Alan McLachlan (Research Institute of Scripps Clinic at La Jolla, CA, USA) kindly provided PLC/ PRF/5 human HCC cells. HepG2 cells were purchased from ATCC (Rockville, MD, USA). Cool calf 1 and the other chemicals were purchased from Sigma Co. (St. Louis, MO, USA). The mammalian expression vector pCEP was purchased from Invitrogen (Carlsbad, CA, USA). p21 WAF1/CIP1 and p53 antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). cdk2 and cdk4 antibodies, rabbit anti-mouse IgG and protein A/agarose were purchased from Transduction Laboratories (Lexington, KY, USA).
Cell culture
Two human liver cancer cell lines were employed because they represent different states of differentiation. HepG2 is a well-differentiated cell line and derived from human hepatoblastoma. PLC/ PRF/5 is a poorly differentiated cell line and derived from HCC of a patient with HBV. HepG2 and PLC/PRF/5 cells were grown in MEM containing 5% Cool Calf 1 (Sigma Co. St. Louis, MO, USA) supplemented with 10 mmol L 71 L-glutamine, 1 mmol L 71 sodium pyruvate, 100 IU ml 71 penicillin and 100 mg ml 71 streptomycin (GIBCO -BRL, Burlington, ON, Canada) in Falcon 75 cm flasks. Cultures were maintained at 378C in a humidified atmosphere of 95% O 2 and 5% CO 2 .
RNA extraction and Northern blot analyses
Total RNA of HepG2 and PLC/PRF/5 cells was extracted by a Lithium chloride/Urea method (Gong et al, 1995) and the polyA-RNA was isolated by employing oligo-dT cellular column (Aviv and Leder, 1972) . Northern blot analysis was performed using a-32 P-dCTP-labelled full-length human p21 WAF1/CIP1 cDNA and b-actin probes as previously described (Gong et al, 1995) . Briefly, 6 mg of polyA-RNA was separated through 1% agarose gel, transferred onto GT-zeta nylon membrane (Bio-Rad, Burlington, ON, Canada), hybridized overnight with the probes at 428C and washed as per the manufacturer's instructions.
Transient transfection
1610
5 cells were seeded in 6-well plate one day before the transfection. Mock (water), pCEP or pCEP-WAF1 was mixed with LipofectinAMINE and the mixtures were then incubated with cells for 24 h. After 24 h, cells were washed and incubated with culture media without antibiotics for a further 24 h followed by culturing in completed media for 36 h to allow expression of p21 WAF1/CIP1 gene.
Cell proliferation assay
For cell doubling time, both cell lines were plated at 1610 5 cells in 6-well plates, cell numbers were counted at days 2 and 6 after seeding. Cell doubling time was calculated according to the formula (doubling time=t6log 2/log Nt/Ni, where t=time between the count, Nt=cell number at day 6 and Ni=cell number at day 2) as described previously (Gong et al, 1991) . For 3 H-thymidine incorporation assays, cells transfected as delineated above were labelled with 10 mCi of 3 H-thymidine (specific activity 45 Ci mmol 71 , Amersham, Oakville, ON, USA) for 2 h, fixed in 10% trichloroacetic acid and lysed in 400 ml of 0.2M sodium hydroxide. One hundred ml of the cell lysate was employed to measure [
3 H]thymidine incorporation with a LKB liquid scintillation counter (Wallac, Turku, Finland) and 10 ml of the cell lysate was used to measure protein content by the Lowry technique.
The Western blot analyses
Cells non-transfected or transfected with mock, pCEP vector, and pCEP-WAF1 as delineated above were lysed in 100 ml of 26 loading buffer (125 mmol L 71 Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.1% bromophenol blue and 2.5% b-mercaptoethanol). Twenty mg of cell lysate from each sample was separated in a 15% polyacrylamide/SDS gel, transferred onto Nitroplus-2000 membranes (Micron Separations Inc. Westborough, MA, USA) and incubated with antibodies against p53, p21 WAF1/CIP1 , cdk2 and cdk4 respectively. Immunoreactive bands were visualized by using the ECL (enhanced chemiluminescence) detection method (Amersham, Arlington Heights, IL, USA) (Gong et al, 1995) . 
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Immunokinase assay
Immunokinase assay was performed following a protocol from Transduction Laboratories (Lexington, KY, USA). Briefly, cells with no transfection and transfection of mock, pCEP vector, and pCEP-WAF1 as described above were lysed in 1 ml cold lysis buffer (10 mmol L 71 Tris-HCl pH 7.4, 1.0% Triton X-100, 0. 
RESULTS
We employed two human liver cancer cell lines to investigate the direct effect of p21 WAF1/CIP1 on these cells. The two human liver cancer cell lines -HepG2 and PLC/PRF/5 exhibited very different expression pattern of p53, p21 WAF1/CIP1 , cdk2 and cdk4. By Western blot analyses, p53, p21 WAF1/CIP1 , cdk2 and cdk4 can be detected in HepG2 cells while p53, cdk2 and cdk4 were observed in PLC/PRF/5 cells ( Figure 1A) . Moreover, the abundance of p53 protein in HepG2 cells was higher than that of PLC/PRF/5 cells. Furthermore, cdk4 protein level was higher in PLC/PRF/5 cells than in HepG2 cells ( Figure 1B Cyclin-dependent kinase inhibitor and human liver cancer cells Y Gong et al mRNA was expressed at low level in PLC/PRF/5 cells as compared to that in HepG2 cells ( Figure 1C) . Furthermore, the expression of p21 WAF1/CIP1 was related to longer cell doubling time (HepG2 cells 44+4 h vs PLC/PRF/5 cells 29+3 h, P50.05). Under the same transfection condition, the p21 level as the result of transfection in PLC/PRF/5 cells was four times than that in the HepG2 cells. However, the total p21 levels in PLC/PRF/5 cells after transfection was about twice of that in the HepG2 cells (Figure 2) .
The effects of p21 WAF1/CIP1 on cell proliferation of two human liver cancer cells were shown in Figure 3 . The p21 WAF1/CIP1 inhibited cell proliferation of both HepG2 and PLC/PRF/5 cells with different extent. Although lower than pCEP vector control, the p21 WAF1/CIP1 did not significantly inhibit HepG2 cell proliferation ( Figure 3A) . However, the p21 WAF1/CIP1 inhibited PLC/PRF/5 cell proliferation in a dose-dependent manner. Progressive increases in the amount of transfected p21 WAF1/CIP1 cDNA resulted in a progressive inhibition of PLC/PRF/5 cell proliferation until maximum inhibition was obtained at 2 mg of the p21 WAF1/CIP1 cDNA. When compared to cell proliferation associated with transfection of the pCEP vector alone, the differences were statistically significant (P50.01, Figure 3B ). Moreover, inhibition of [ 3 H]thymidine incorporation was correlated with the expression of p21 WAF1/CIP1 protein in PLC/PRF/5 cells ( Figure 3C ). To elucidate the mechanism of p21 WAF1/CIP1 inhibition of cell proliferation, we examined the p21 WAF1/CIP1 regulation of cdk2 and cdk4 in both PLC/PRF/5 and HepG2 cells. Our results showed that the p21 WAF1/CIP1 did not alter either cdk2 or cdk4 proteins in these cells ( Figure 4A ). The cdk2 kinase activity was further examined by immunokinase assay. Although cdk2 kinase activity was higher in PLC/PRF/5 cells than that in HepG2 cells, the p21 WAF1/CIP1 reduce cdk2 kinase activity by 20% in both cells ( Figure 4B ).
DISCUSSION
p21
WAF1/CIP1 was identified as a potential mediator of p53 protein and a co-immunoprecipitated protein of cyclin D1 (Xiong et al, 1992; el-Deiry et al, 1993) . Extensive studies reveal that p21 WAF1/ CIP1 involves in the progression of cell cycle. It inhibits several cyclin-cdk activities and also is a component of proliferating nuclear antigen (PCNA) and DNA polymerase d complexe (Sherr and Roberts, 1995) . The p21 WAF1/CIP1 protein contains two functional domains, which are mediated in the inhibition of cdk kinase and binding of PCNA. The amino end of p21 WAF1/CIP1 contains an inhibitory domain of cdk, which inhibits cyclin D and E associated cdks activities. The carboxyl end of p21 WAF1/CIP1 mediates the PCNA-binding and activity of DNA polymerase d (Chen et al, 1995; Luo et al, 1995; Nakanishi et al, 1995; Warbrick et al, 1995) . Our results showed that p21 WAF1/CIP1 inhibited [ 3 H]thymidine incorporation and reduced cdk2 kinase activity in human liver cancer cells but did not affect expression of cdk2 and cdk4. The findings suggest that the transfected p21 WAF1/CIP1 likely has no apparent effect on the expression of cdks but may block the ability of PCNA to activate DNA polymerase d and the cdk kinase activity in human liver cancer cells. The distinguished action of p21 WAF1/ CIP1 was demonstrated in a SV40-based DNA replication system. In this in vitro DNA replication system, p21 WAF1/CIP1 was able to block PCNA-activated DNA polymerase d activity without the participation of cyclin-bound cdks (Flores-Rozas et al, 1994; Waga et al, 1994) .
The role of p21 WAF1/CIP1 in tumorgenesis of human hepatocellular carcinoma (HCC) is not clear. However, reduction of p21 WAF1/ CIP1 mRNA and protein abundance was observed in human HCC (Naka et al, 1998; Qin et al, 1998) . Studies of p21 WAF1/CIP1 mRNA abundance in human HCC from Chinese and Japanese groups showed some controversies (Naka et al, 1998; Qin et al, 1998) . The difference could be due to the infection of different hepatitis viruses as well as non-viral infection. One of the Japanese groups showed that HCC developed from p53-altered and HCV infected patients exhibited reduced p21 WAF1/CIP1 protein abundance while there was little change of p21 WAF1/CIP1 protein level in those patients with HBV infection or no viral infection (Shi et al, 2000) . Their finding was supported by that HCV core protein inhibited the promoter activity of p21 WAF1/CIP1 gene (Ray et al, 1998) . But the reduction of p21 WAF1/CIP1 mRNA abundance in HCC could be more complicated because of p53 gene status in WAF1/CIP1 on cdk2 and cdk4 protein abundance in these cells. Twenty mg of each cell lysate was used for Western blot analyses and the experiment was repeated on three occasions. (B) Shows the effect of cdk2 kinase activity in these cells. The cell lysates (1 mg of each) were immunoprecipitated with anti-CDK2 antibody and the immunoprecipitates were incubated with a reaction solution for in vitro phosphorylation of histone H1 as described in Materials and Methods. Samples were then electrophoresis and phosphorylated histone 1 was visualized by autoradiography of the slab gels. (C) Displays the histogram of cdk2 kinase activity. The data was generated from four separated experiments and represented as mean+s.e. The no transfection was arbitrarily set as 1.
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HCC. In this study, we employed a HCC cell line -PLC/PRF/5 cells, which were derived from an African man with HBV infection and carry HBV genome (Aden et al, 1979; Koch et al, 1984 (Hsu et al, 1993) , the absence of p21 WAF1/CIP1 protein in PLC/ PRF/5 cells could be related to p53 gene rather than viral infection. It is consistent with HepG2 cells because HepG2 cells carry wild type p53 gene and no HBV genome (Hosono et al, 1991) . In these cells, the p21 WAF1/CIP1 level is higher than that in PLC/PRF/5 cells. Therefore, the p21 WAF1/CIP1 mRNA abundance in human HCC may be dependent on both the type of viral infection and p53 gene status.
One of our findings was that the expression of p21 WAF1/CI and cdks could determine whether the p53 deficient cancer cells proliferated or not (Zhang et al, 1994; Shima et al, 1998) . In our case, that PLC/PRF/5 cells expressed no p21 WAF1/CIP1 but higher cdk4 level made it more susceptible to the inhibitory effect of p21 WAF1/CIP1 . HepG2 cells expressed p21 WAF1/CIP1 and had lower cdk4 level, therefore, HepG2 cells were less sensitive to the effect of p21 WAF1/CIP1 . In conclusion, our present study has shown that: (a) HepG2 and PLC/PRF/5 have distinguished expression pattern of p53, p21 WAF1/ CIP1 , and cdk4; (b) although both cells exhibited the same level of cdk2, activity of cdk2 was higher in PLC/PRF/5 cells than in HepG2 cells; (c) p21
WAF1/CIP1 inhibited [ 3 H]thymidine incorporation and cdk2 kinase activity in both HepG2 and PLC/PRF/5 cells, however, the most significant inhibition was observed in PLC/PRF/5 cells; (d) since p21 WAF1/CIP1 inhibited DNA synthesis of human liver cancer cells, p21 WAF1/CIP1 could be a target gene for the treatment of human HCC.
